IBRX
ImmunityBio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.08
−1.34%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−10.2x
Market Cap
$8.56B
MomentumView details →
1D Return
−1.34%
YTD Return
+309.85%
RSI (14)
54.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−10.2x
Market Cap
$8.56B
RSI (14)
54.9
MomentumView details →
1D Return
−1.34%
YTD Return
+309.85%
SummaryUpdated Jun 1, 2026
ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage biotechnology company founded in 2014 and headquartered in San Diego, California. The company went public in 2015 and focuses on developing innovative therapies and vaccines to treat cancers and infectious diseases. ImmunityBio operates at the cutting edge of immunotherapy and cell therapy, leveraging the body's immune system to fight diseases that have traditionally been difficult to treat.
Similar companies
Latest newsMore news →
Bell & Brown Wealth Advisors LLC acquired a new stake in ImmunityBio, Inc. by purchasing 75,050 shares worth approximately $657,000 in the second quarter.16d agoBank of America Corp DE increased its stake in ImmunityBio, Inc. by 2.7% during the first quarter, acquiring an additional 65,340 shares, according to its SEC disclosure.16d ago